ES2422877R1 - Combinacion y composicion para el tratamiento de obesidad - Google Patents

Combinacion y composicion para el tratamiento de obesidad

Info

Publication number
ES2422877R1
ES2422877R1 ES201390069A ES201390069A ES2422877R1 ES 2422877 R1 ES2422877 R1 ES 2422877R1 ES 201390069 A ES201390069 A ES 201390069A ES 201390069 A ES201390069 A ES 201390069A ES 2422877 R1 ES2422877 R1 ES 2422877R1
Authority
ES
Spain
Prior art keywords
combination
composition
obesity
obesity treatment
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
ES201390069A
Other languages
English (en)
Other versions
ES2422877B1 (es
ES2422877A2 (es
Inventor
Pelaez Juan Pablo Senosiain
Hernandez Gustavo Barranco
Salgado Lopez Raul Garcia
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Laboratorios Senosiain SA de CV
Original Assignee
Laboratorios Senosiain SA de CV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=46313244&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2422877(R1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Laboratorios Senosiain SA de CV filed Critical Laboratorios Senosiain SA de CV
Publication of ES2422877A2 publication Critical patent/ES2422877A2/es
Publication of ES2422877R1 publication Critical patent/ES2422877R1/es
Application granted granted Critical
Publication of ES2422877B1 publication Critical patent/ES2422877B1/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/167—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
    • A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
    • A61K9/5047—Cellulose ethers containing no ester groups, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C39/00—Compounds having at least one hydroxy or O-metal group bound to a carbon atom of a six-membered aromatic ring
    • C07C39/205—Compounds having at least one hydroxy or O-metal group bound to a carbon atom of a six-membered aromatic ring polycyclic, containing only six-membered aromatic rings as cyclic parts with unsaturation outside the rings
    • C07C39/21—Compounds having at least one hydroxy or O-metal group bound to a carbon atom of a six-membered aromatic ring polycyclic, containing only six-membered aromatic rings as cyclic parts with unsaturation outside the rings with at least one hydroxy group on a non-condensed ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D305/00—Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms
    • C07D305/02—Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms not condensed with other rings
    • C07D305/04—Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D305/00—Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms
    • C07D305/02—Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms not condensed with other rings
    • C07D305/10—Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms not condensed with other rings having one or more double bonds between ring members or between ring members and non-ring members
    • C07D305/12—Beta-lactones
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2200/00—Function of food ingredients
    • A23V2200/30—Foods, ingredients or supplements having a functional effect on health
    • A23V2200/332—Promoters of weight control and weight loss
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Child & Adolescent Psychology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Combinación y composición para el tratamiento de obesidad. La presente invención tiene su aplicación en el campo farmacéutico, especialmente en el de combinación y composiciones farmacéuticas que comprenden un inhibidor de la lipasa y una fitoalexina y vehículos o excipientes farmacéuticamente aceptables; la presente invención también se relaciona con el proceso de fabricación de composiciones que contienen la combinación y el uso de dicha composición en el tratamiento de padecimientos de sobrepeso, obesidad y problemas de salud relacionados.
ES201390069A 2010-12-21 2011-12-16 Combinación y composición para el tratamiento de obesidad Active ES2422877B1 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
MX2010014484A MX336980B (es) 2010-12-21 2010-12-21 Combinacion y composicion para el tratamiento de obesidad.
MX/A/2010/014484 2010-12-21
PCT/IB2011/055723 WO2012085785A1 (es) 2010-12-21 2011-12-16 Combinación y composición para el tratamiento de obesidad

Publications (3)

Publication Number Publication Date
ES2422877A2 ES2422877A2 (es) 2013-09-16
ES2422877R1 true ES2422877R1 (es) 2013-09-26
ES2422877B1 ES2422877B1 (es) 2014-07-17

Family

ID=46313244

Family Applications (1)

Application Number Title Priority Date Filing Date
ES201390069A Active ES2422877B1 (es) 2010-12-21 2011-12-16 Combinación y composición para el tratamiento de obesidad

Country Status (15)

Country Link
US (1) US9433602B2 (es)
AR (1) AR084435A1 (es)
BR (1) BR112013015489A2 (es)
CA (1) CA2822213C (es)
CL (1) CL2013001731A1 (es)
CO (1) CO6751242A2 (es)
CR (1) CR20130298A (es)
DO (1) DOP2013000144A (es)
ES (1) ES2422877B1 (es)
GB (1) GB2500357B (es)
GT (1) GT201300169A (es)
MX (1) MX336980B (es)
PE (1) PE20140697A1 (es)
RU (1) RU2608928C2 (es)
WO (1) WO2012085785A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10743813B2 (en) 2014-09-11 2020-08-18 Rattan Nath Diabetes control using postprandial feedback
WO2016168388A2 (en) 2015-04-14 2016-10-20 Palatin Technologies, Inc. Therapies for obesity, diabetes and related indications

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001000205A1 (en) * 1999-06-24 2001-01-04 Knoll Aktiengesellschaft Pharmaceutical composition containing sibutramine and orlistat
WO2004080450A2 (en) * 2003-03-13 2004-09-23 Fournier Laboratories Ireland Limited Combined use of a fibrate and orlistat for the treatment of obesity
US20060111435A1 (en) * 2003-12-29 2006-05-25 President And Fellows Of Harvard College Compositions for treating or preventing obesity and insulin resistance disorders
WO2007008548A2 (en) * 2005-07-07 2007-01-18 Sirtris Pharmaceuticals, Inc. Methods and related compositions for treating or preventing obesity, insulin resistance disorders, and mitochondrial-associated disorders
WO2010045522A2 (en) * 2008-10-16 2010-04-22 Metabolous Pharmaceuticals, Inc. Combination therapies for the treatment of obesity

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19539361A1 (de) * 1995-10-23 1997-04-24 Basf Ag Verfahren zur Herstellung von mehrschichtigen, festen Arzneiformen zur oralen oder rektalen Verabreichung
WO2006076191A2 (en) * 2005-01-10 2006-07-20 Elc Management Llc Discontinuous surface coating for particles
US7771632B2 (en) * 2006-05-15 2010-08-10 American Leistritz Extruder Corp. Continuous melt spheronization apparatus and process for the production of pharmaceutical pellets
BRPI0817053A2 (pt) * 2007-09-17 2015-03-24 Reddys Lab Ltd Dr Formulações farmacêuticas de orlistat

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001000205A1 (en) * 1999-06-24 2001-01-04 Knoll Aktiengesellschaft Pharmaceutical composition containing sibutramine and orlistat
WO2004080450A2 (en) * 2003-03-13 2004-09-23 Fournier Laboratories Ireland Limited Combined use of a fibrate and orlistat for the treatment of obesity
US20060111435A1 (en) * 2003-12-29 2006-05-25 President And Fellows Of Harvard College Compositions for treating or preventing obesity and insulin resistance disorders
WO2007008548A2 (en) * 2005-07-07 2007-01-18 Sirtris Pharmaceuticals, Inc. Methods and related compositions for treating or preventing obesity, insulin resistance disorders, and mitochondrial-associated disorders
WO2010045522A2 (en) * 2008-10-16 2010-04-22 Metabolous Pharmaceuticals, Inc. Combination therapies for the treatment of obesity

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
01/10/2010, YUN et al. Possible anti-obesity therapeutics from nature - A review.PHYTOCHEMISTRY, 20101001 PERGAMON PRESS, GB 01/10/2010 VOL: 71 No: 14-15 Pags: 1625 - 1641 ISSN 0031-9422, página 1626, columna 2, líneas4-8, página 1632, columnas 1 y 2, *

Also Published As

Publication number Publication date
BR112013015489A2 (pt) 2018-05-15
ES2422877B1 (es) 2014-07-17
GB2500357B (en) 2017-09-06
MX336980B (es) 2016-02-09
CA2822213C (en) 2018-06-19
ES2422877A2 (es) 2013-09-16
WO2012085785A1 (es) 2012-06-28
DOP2013000144A (es) 2013-10-15
AR084435A1 (es) 2013-05-15
MX2010014484A (es) 2012-06-21
GT201300169A (es) 2014-04-04
CL2013001731A1 (es) 2014-01-10
GB2500357A (en) 2013-09-18
US9433602B2 (en) 2016-09-06
RU2013127794A (ru) 2015-01-27
CO6751242A2 (es) 2013-09-16
CR20130298A (es) 2013-07-09
RU2608928C2 (ru) 2017-01-26
GB201312583D0 (en) 2013-08-28
PE20140697A1 (es) 2014-06-25
US20130316005A1 (en) 2013-11-28
CA2822213A1 (en) 2012-06-28

Similar Documents

Publication Publication Date Title
UY32456A (es) Composicion famaceutica, forma farmaceutica, procedimiento para su preparación, metodos de tratamiento
CL2008001002A1 (es) Compuestos derivados de oxazolidinona; composicion farmaceutica que comprende a dichos compuestos; y su uso para preparar un medicamento para tratar una infeccion bacteriana.
MA33803B1 (fr) Inhibiteur de bromodomaine de benzodiazépine
CR20120008A (es) Compuestos y composiciones para el tratamiento de enfermedades parasitarias
EA201200550A1 (ru) Фармацевтические композиции, включающие bi-1356 и метформин
CL2008001003A1 (es) Compuestos derivados de oxazolidinona; composicion farmaceutica que comprende a dichos compuestos; y su uso para preparar un medicamento para tratar una infeccion bacteriana.
CL2012003415A1 (es) Compuestos derivados de 2-oxo-piperidina y 1,1-dioxido-tiazina, inhibidores de mdm2; composicion farmaceutica que los comprende; y su uso para el tratamiento del cancer .
CL2011000214A1 (es) Composicion farmaceutica que comprende progesterona micronizada y aceite de cartamo tipo ii; y uso para el tratamiento de una condicion relacionada con la insuficiencia de secrecion de progesterona.
BR112013031794A2 (pt) novos derivados de oxintomodulina e composição farmacêutica para o tratamento da obesidade compreendendo os mesmos
CL2009000426A1 (es) Compuestos derivados de carbociclil/heterociclil-piridin-2-il-urea, inhibidores de topoisomerasa iv bacteriana; composicion farmaceutica; y su uso para el tratamiento de infecciones bacterianas
UY33183A (es) Compuestos inhibidores de virus flaviviridae, composición farmaceutica que los contiene y su uso en la manufactura de un medicamento
TN2011000471A1 (en) Pharmaceutical composition presenting anti-inflammatory properties
CL2011000604A1 (es) Compuestos derivados de multiheteroarilo, inhibidores de h-pgds, composicion farmaceutica que los comprende; utiles en el tratamiento de enfermedades inflamatorias y alergicas.
UY33530A (es) Composiciones farmacéuticas para el tratamiento de enfermedades respiratorias e inflamatorias
AR082215A1 (es) Composicion farmaceutica agradable al paladar
CL2012003265A1 (es) Polisacarido de semillas de tamarindo para usarse en el tratamiento de enfermedades infecciosas; composicion farmacéutica y/o dermocosmética antiinflamatoria que contiene dicho polisacárido; uso de un polisacárido de semilla de tamarindo.
PE20150167A1 (es) (r)-nifuratel, su uso para el tratamiento de las infecciones y sintesis de (r) y (s)-nifuratel
EA201171414A1 (ru) Ингибиторы белков семейства iap
UY33305A (es) Compuestos heterocíclicos inhibidores de DGAT1
CL2013000335A1 (es) Forma altamente cristalina de valsartan; proceso para prepararla; composicion farmaceutica que la comprende y uso en el tratamiento de la hipertension.
ECSP15050273A (es) Formulación oral para el tratamiento de enfermedades cardiovasculares
CL2015001502A1 (es) Composición farmacéutica que comprende desloratadina y prendnisolona y uso de la misma.
ECSP13012765A (es) Combinación y composición para el tratamiento de obesidad
CO6751242A2 (es) Combinación y composición para el tratamiento de obesidad
CL2008003711A1 (es) Proceso para preparar una forma de dosificación farmaceutica que comprende florfenicol o un análogo de este; y para recuperar florfenicol o un análogo de una composición farmacéutica.

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 2422877

Country of ref document: ES

Kind code of ref document: B1

Effective date: 20140717